<DOC>
	<DOCNO>NCT01349192</DOCNO>
	<brief_summary>Purpose : There recent , rapid increase prevalence Methicillin-resistant Staphylococcus aureus ( MRSA ) among patient Cystic Fibrosis ( 22 % across US CF center 2009 ) . Some epidemiologic study suggest possible bad outcome , recent analysis show chronic intermittent MRSA . Given chronic difficult treat lung infection CF unclear onset MRSA approach . This randomize , control , interventional study seek determine early eradication protocol effective eradication MRSA provide opportunity obtain data regard early clinical impact new isolation MRSA . Participants : Cystic fibrosis patient new isolation MRSA respiratory culture routine clinic visit . Procedures ( method ) : Randomized , open-label , multi-center study compare use eradication protocol observational group receive current standard care i.e . treatment MRSA pulmonary exacerbation .</brief_summary>
	<brief_title>Early Methicillin-resistant Staphylococcus Aureus ( MRSA ) Therapy Cystic Fibrosis ( CF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>1 . Male female ≥ 4 ≤ 45 year age Screening Visit . 2 . Documentation CF diagnosis evidence one clinical feature consistent CF phenotype one follow criterion : sweat chloride ≥ 60 mEq/liter quantitative pilocarpine iontophoresis test ( QPIT ) two wellcharacterized mutation cystic fibrosis transmembrane conductive regulator ( CFTR ) gene Abnormal nasal potential difference ( change NPD response low chloride solution isoproteronol less 5 mV ) 3 . First OR early repeat MRSA colonization define : First MRSA colonization : first document isolation MRSA respiratory tract occur ≤ 6 month prior screen OR Early repeat MRSA colonization : MRSA previously isolate respiratory tract ( ≤ 2 time ) , follow least 1 year document negative culture MRSA note : At least 2 culture perform least 3 month apart document 1 year culture negativity . Each culture document collect least 1 week end antibiotic prescription MRSA activity . Patient recently positive MRSA respiratory tract ( within 6 month prior screen ) 4 . Clinically stable significant change health status within 14 day prior screen 5 . Written informed consent ( assent applicable ) obtain subject subject 's legal representative ability subject comply requirement study A repeat culture respiratory tract obtain screen positive able enter study . 1 . Received antibiotic activity MRSA within 28 day prior screen ( see study manual list antibiotic ) 2 . Use investigational agent within 28 day prior screen 3 . For subject ≥ 6 year age : FEV1 screen &lt; 30 % predict age base Wang ( male &lt; 18 year , females &lt; 16 year ) Hankinson ( male ≥ 18 year , females ≥ 16 year ) standardize equation 4 . MRSA screening culture resistant rifampin OR resistant TMP/SMX minocycline 5 . History intolerance oral rifampin , topical chlorhexidine mupirocin 6 . History intolerance TMP/SMX minocycline 7 . &lt; 8 year age either allergic intolerant TMP/SMX screen MRSA resistant TMP/SMX 8 . ≥ 8 year age allergic intolerant TMP/SMX screen MRSA resistant minocycline 9 . ≥ 8 year age allergic intolerant minocycline screen MRSA resistant TMP/SMX 10 . For female child bear potential : pregnant , breastfeeding , unwilling use barrier contraception Day 15 study 11 . Abnormal renal function Screening , define estimate creatinine clearance &lt; 50 mL/min use CockcroftGault equation 12 . Abnormal liver function time screening , define ≥2x upper limit normal ( ULN ) , serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) 13 . History solid organ hematological transplantation 14 . Presence condition abnormality opinion Investigator would compromise safety patient quality data .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>MRSA</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Early Infection</keyword>
	<keyword>Treatment</keyword>
</DOC>